Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

ZOLL to use Vicor patented technology

ZOLL Medical has signed a licensing and development agreement with Vicor Technologies as part of which Zoll will use Vicor's patented, proprietary PD2i nonlinear algorithm into its products to enable the ability to predict patient's risk of tachyarrhythmia.

The algorithm is found as a valid metric for risk stratifying specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure.

It will also help diabetics for the presence of diabetic autonomic neuropathy, trauma victims for imminent death absent immediate lifesaving intervention, and ICU patients for mortality risk stratification.

ZOLL will add Vicor’s PD2i technology in existing and future products to allow real time analysis of patient physiological information and risk prediction to facilitate earlier intervention in patients and prevent serious events.